Project Grant HT9425261E312
Award Date 9/1/26
Completion Date 8/31/30
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $1.424 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded August 1, 2025, with a performance period through July 31, 2029. The award supports research to expand the targetable tumor antigen repertoire of renal cell carcinoma, positioning the work within DHA's broader portfolio of hypothesis-driven biomedical research...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $1,014,596 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on July 15, 2026. The award, which extends through July 14, 2029, supports research to optimize immunotherapy approaches for pediatric solid tumors. This research initiative aligns with the DHA's portfolio of clinical trials and translational research addressing Service Member...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $559,999 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to support the development of novel digenic combination therapies for pancreatic cancer treatment. The award period runs from September 1, 2026 through August 31, 2028. This funding supports basic and applied biomedical research addressing medical needs relevant to the military population,...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1,099,614 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective June 1, 2026 through May 31, 2030. The award funds research to define a Retinoblastoma (RB) functional subtype of endometrial cancer. This research initiative aligns with the DHA's mission to support basic and applied biomedical research addressing Service Member...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $4.199 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2026 through August 31, 2030. The award funds the development and optimization of B7-H3 chimeric antigen receptor (CAR) T cells for pediatric and young adult patients with sarcomas and other B7-H3-positive solid tumors. This research initiative represents an...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.1 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026, through May 31, 2030. The project, titled "LISTEN: Augmenting and Facilitating Communication in Brain Tumor Patients with Aphasia," supports biomedical research addressing Service Member health and military-relevant medical conditions. The four-year...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $723,699 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 15, 2026, through July 14, 2029. The award supports research aimed at optimizing immunotherapy for pediatric solid tumors. Based on DHA's funding portfolio and Dana-Farber's research capabilities, this project likely involves mechanistic studies and...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $752,238 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2026 through June 30, 2029. The award supports the development and validation of explainable artificial intelligence (AI) methodologies for predicting melanoma progression and survival outcomes. This three-year initiative aligns with the DHA's mission to...
- Summary Dana-Farber Cancer Institute, Inc. received a $2.0 million Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2026, for the Prostate Cancer Clinical Trials Consortium. The award, which extends through September 29, 2030, supports clinical trial coordination and research infrastructure designed to advance prostate cancer treatment options relevant to Service Members and the military...
- The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...